Search International and National Patent Collections
|1. (WO2017020291) NOVEL ANTI-PD-L1 ANTIBODIES|
|Applicants:||WUXI BIOLOGICS (SHANGHAI) CO. LTD.
OPEN MONOCLONAL TECHNOLOGY, INC.
|Title:||NOVEL ANTI-PD-L1 ANTIBODIES|
The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1 to PD-1, and therefore block the inhibitory function of PD-L1 on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.